CHF Solutions today said it submitted a patent application for a system to dramatically improve and simplify venous access for its Aquadex system.
The new system would simplify venous access for Aquadex’s ultrafiltration for multiple continuous renal replacement therapy (CRRT) modalities. It is designed to make CRRT therapies available to all patients through easy-to-use peripheral venous access.
Aquadex SmartFlow provides ultrafiltration therapy through central or peripheral venous access. The new technology goes further to establish and maintain peripheral access for multiple therapy types.
“Access to innovative care solutions for patients with the cardio-kidney disease is our priority at CHF Solutions,” president and CEO Nestor Jaramillo said in a news release. “Ease of use and specifically, the option for peripheral venous access, removes burdens for clinicians to put patients on ultrafiltration therapies. We’ll continue to invest in and design new products to meet this need and in making our Aquadex ultrafiltration system easy to use, flexible in application, and predictable in outcomes.”
The Aquadex SmartFlow system removes excess fluid from patients with hypervolemia. It is indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more and whose fluid overload is unresponsive to medical management.
